Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from November 9, 2025

Partial Published before the outcome was known, scored automatically when the window closed on February 7, 2026.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted

$98.50 – $100.50Entry zone — fair-value band

$100.02Published — price the day we called it

$118.02Target — the price the thesis aimed for

$105.65Peak — highest point inside the window, not a realized return

$76.27Window close — end-of-window price, context only

What happened

Partial

Reached 31% of the predicted growth at its peak, without hitting the target.

Peak price

$105.65

peak on November 13, 2025 — not a realized return

Peak gain

+5.6%

peak, from the publication price

Window close

$76.27

end-of-window price, context only

Days to target

—

Window

November 9, 2025 – February 7, 2026

The thesis — published November 9, 2025

Predicted growth

+18%

over the measurement window

Target price

$118.02

the price the thesis aimed for

Entry zone

$98.50 – $100.50

the fair-value band we waited for

Price at publication

$100.02

published November 9, 2025

Confidence

65%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Boston Scientific looks steady and likely to keep trending up in medical devices. It bought BioEnvelope for $88M, adding depth to its product line and helping fund future projects like NXT-41x. The share price has been calm and slightly rising, which can suit buying near recent price levels. Hospitals are still doing many procedures, but pressure on prices and tight budgets could slow orders, so that risk should be watched.

Primary drivers

Small acquisition adds products and helps fund new pipeline work projects
Price action has steadied and is edging upward in recent weeks
Investors favor high-quality medical device makers right now overall
Hospitals are performing many procedures, supporting device demand

How it played out

BSX: target was not reached by window end

Lyra published BSX at 100.02 on 2025-11-09, with 18% expected growth and a target of 118.02. The thesis pointed to the BioEnvelope purchase, steadier recent price action, investor interest in medical device makers, and hospital procedure demand. It also noted pricing pressure and tight hospital budgets as risks.

Inside the window, BSX rose to 105.65 on 2025-11-13, a 5.6% peak gain. It stayed below the target. By 2026-02-07, it ended at 76.27. The thesis partially played out early, but it missed the target and finished well below the publication price.

What happened during the window

On 2026-01-15, Boston Scientific announced a deal to buy Penumbra in a cash-and-stock transaction. On 2026-02-04, Investors.com reported fourth-quarter results and said shares fell after electrophysiology sales missed expectations.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals